Cellectar Biosciences, Inc.
CLRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $52 | $0 | $0 | $0 |
| Gross Profit | -$52 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,523 | $2,390 | $3,427 | $6,209 |
| G&A Expenses | $0 | $3,648 | $2,974 | $6,536 |
| SG&A Expenses | $2,275 | $3,648 | $2,974 | $6,536 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,798 | $6,038 | $6,401 | $12,745 |
| Operating Income | -$4,851 | -$6,038 | -$6,401 | -$12,745 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $407 | $590 | -$203 | $10,455 |
| Pre-Tax Income | -$4,444 | -$5,448 | -$6,604 | -$2,289 |
| Tax Expense | $0 | $0 | $0 | $66 |
| Net Income | -$4,444 | -$5,448 | -$6,604 | -$2,355 |
| % Margin | – | – | – | – |
| EPS | -1.41 | -3.39 | -4.3 | -1.68 |
| % Growth | 58.4% | 21.2% | -155.9% | – |
| EPS Diluted | -1.41 | -3.39 | -4.3 | -1.68 |
| Weighted Avg Shares Out | 3,162 | 1,609 | 1,536 | 1,397 |
| Weighted Avg Shares Out Dil | 3,162 | 1,609 | 1,536 | 1,398 |
| Supplemental Information | – | – | – | – |
| Interest Income | $113 | $88 | $137 | $244 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $52 | $56 | $56 | $69 |
| EBITDA | -$4,392 | -$5,982 | -$6,345 | -$12,676 |
| % Margin | – | – | – | – |